
|Articles|June 11, 2014
- June 2014
- Volume 18
- Issue 1
Cyclosporine Treats Severe Poison Ivy in Case Study
Advertisement
In a case study presented at the American Academy of Allergy Asthma and Immunology Annual Meeting, researchers successfully treated a 33-year-old patient with yearly, unavoidable poision ivy exposure without using steroids.
Instead, researchers used a 200-mg/day cyclosporine regimen during the patient's exposure period, which resulted in a resolution of poison ivy symptoms after 6 weeks of therapy. The dose was also decreased to 100 mg every other day without the poison ivy symptoms returning, and without the need for topical or systemic corticosteroids.
Articles in this issue
over 12 years ago
Consuming Antioxidants and Fish May Prevent Macular Degenerationover 12 years ago
Test May Aid Diagnosis of Fungal Nail Infectionover 12 years ago
18 Years Strong!over 12 years ago
Pharmacy Times: Leading the Wayover 12 years ago
Odd Allergies: OTC Answers?over 12 years ago
Vitamin D Supplements: Reaping the Benefits from the Right Amountover 12 years ago
Teens Frequently Given Opioids for Headacheover 12 years ago
For Plaque Removal, Straight Toothbrush Beats Angledover 12 years ago
Aspirin May Reduce Ovarian Cancer RiskAdvertisement
Related to this article

Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.

The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.

Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.

Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
5


